Funded Projects › HORIZON
STRATIFYHF · Artificial intelligence-based decision support system for risk stratification and early detection of heart failure in primary and secondary care
Heart failure (HF) is a pandemic currently affecting up to 15 million people in Europe. It is a complex clinical syndrome presenting with impaired heart function and is associated with poor quality of life for patients and high healthcare costs. There is a high clinical demand for novel artificial intelligence (AI) tools which will facilitate risk stratification, early diagnosis, and disease progression assessment in HF. Such tools are essential to allow prompt initiation of evidence-based prevention and treatment strategies which will improve patient quality of life, reduce morbidity and mortality and the HF burden on healthcare. STRATIFYHF aims to develop, validate and implement the first AI-based, decision support system (DSS) for risk stratification, early diagnosis, and disease progression assessment in HF to accommodate both primary and secondary care clinical needs. The DSS will integrate patient-specific demographic and clinical data using existing and novel technologies and establish AI-based tools for risk stratification and HF prediction using machine learning. Additionally, a mobile app will be developed to empower patients to better manage their condition, and health care professionals to make informed decision in selection of evidence-based HF prevention and treatment strategies. Our multidisciplinary consortium, including three small-to-medium enterprises (SMEs) and two stakeholder organisations, will be guided by medical advice and regulatory and health technology experts to deliver the DSS as a medical class 2b device, reaching TRL 8 by the end of the project. STARTIFYHF will change the way in which HF is diagnosed today and thereby improve the quality and length of patients’ lives and lead to efficient and sustainable healthcare systems by reducing the number of HF-related hospital admissions and unnecessary referrals from primary to secondary care in Europe and beyond.
Consortium · 19 organisations
ISTRAZIVACKO RAZVOJNI CENTAR ZA BIOINZENJERING BIOIRC DOO
RS · €892,500
COVENTRY UNIVERSITY
UK
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
UK
AZIENDA UNITA' SANITARIA LOCALE TOSCANA CENTRO
IT
KLINIKUM DER UNIVERSITAET REGENSBURG
DE · €446,250
UNIVERSITA DEGLI STUDI DI FIRENZE
IT · €436,250
IDRYMA TECHNOLOGIAS KAI EREVNAS
EL · €438,750
UNIVERSITY OF NEWCASTLE UPON TYNE
UK
UDRUZENJE ZA SRCANU SLABOST SRBIJE
RS · €151,875
SERVICIO MADRILENO DE SALUD
ES · €406,250
INSTITUT ZA KARDIOVASKULARNE BOLESTI VOJVODINE
RS
MEDCON INTERNATIONAL BV
NL · €43,132
BCN HEALTH ECONOMICS & OUTCOMES RESEARCH SL
ES · €346,500
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
NL · €452,500
UNIVERSITY OF NOVI SAD, FACULTY OF MEDICINE NOVI SAD
RS · €425,188
AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI
IT
PKNM SOLUTIONS SARL
CH
GPCARDIO BV
NL · €101,243
UNIVERZA V LJUBLJANI
SI · €355,000
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.